IngredientsKutkins is the collective term for a group of pharmacologically active phytochemical compounds found in the plant Picrorhiza kurroa Royle ex Benth. Kutkins are a group of pharmacologically active compounds present in Picrorhiza kurroa Royle (Scrophulariaceae), a plant traditionally known as kutki that possesses an intense bitter taste. The term is sometimes used interchangeably with "kutkin" (singular) to refer to the characteristic bitter principle of the plant. The chemical composition of Picrorhiza kurroa includes kutkin, a bitter glycoside that contains two C-9 iridoid glycosides, Picroside I and Kutakoside.
The plant is popularly known as "Kutki" or "Kurro" and "Indian gentian," and is found at altitudes of 3,000–5,000 m in the north-western Himalayas. It is observed in the mountain range regions of Nepal, Bhutan, Pakistan, China, and India.
The plant has 5–15 cm long leaves, almost all at the base and often withered, which are coarsely toothed and narrowed to a winged stalk. Rhizomes are 15–25 cm long and woody. Flowers are small, pale or purplish blue, borne in cylindric spikes on almost leafless erect stems, about 8 mm and 5-lobed to the middle with much longer stamens. The roots and rhizomes are the parts used for medicinal therapy.
Kutkins-containing supplements appear in a variety of preparations derived from P. kurroa:
Picrorhiza kurroa, commonly called katuka, kutki, or kutaki in India, has been used for centuries in traditional Indian (Ayurvedic) medicine for a variety of ailments. The roots and rhizomes are the parts used for medicinal therapy. In Ayurveda, Picrorhiza kurroa is a reputed remedy for the treatment of liver diseases.
Historically, kutkin has been highly valued in traditional Ayurvedic and Unani medicine for its potent hepatoprotective properties. Ancient healers prescribed Picrorhiza kurroa extracts to address ailments related to liver dysfunction, such as hepatitis, jaundice, and bile disorders. The bitter principles of kutkin were believed to stimulate bile secretion, improving digestion and detoxification.
In addition to liver health, kutkin-rich preparations were used to manage chronic fevers, respiratory conditions, and even skin disorders, due to their anti-inflammatory and antioxidant effects.
Traditional and folk uses of P. kurroa include chronic constipation, skin-related problems, burning sensation, chronic reoccurring fever, jaundice, heart problems, breathing disorders, digestion problems, allergy, tuberculosis, blood-related problems, prediabetes, obesity, as a laxative, cholagogue, and for liver stimulation.
Picrorhiza and Neopicrorhiza have also been used in Traditional Chinese Medicine (TCM), which has referred to the plant as "hu huang lian." In TCM and Asian Ayurvedic medicine, the plant has been used primarily as a hepatoprotective agent, but may also be used for asthma and to reduce inflammation in the lungs.
Previous studies had explored the use of the unprocessed rhizomes of this genus to treat various ailments such as liver disorders, fever, asthma, and jaundice in Indian, Bhutanese, Tibetan, and Chinese traditional medicines.
The root has a bitter, sharp taste and is a valued traditional drug for liver complaints and biliousness, as documented in early 20th-century references on indigenous drugs of India. Picrorhiza has also been used as a traditional remedy against snake venom and to treat scorpion stings.
More than 50 secondary metabolites of Picrorhiza kurroa have been described, including iridoid glycosides. These are mainly iridoids, acetophenones, and cucurbitacins.
Kutkins are a group of pharmacologically active compounds present in Picrorhiza kurroa. The plant is traditionally known as kutki and has an intense bitter taste. In Ayurveda, it is a reputed remedy for the treatment of liver diseases. The chemical composition has been studied and the active constituents are a group of iridoid glycosides known as picrosides and kutkosides.
The active phytochemical in Picrorhiza kurroa is kutkin (the bitter phytochemical), which consists of picrosides and kutkosides. The main picrosides found in kutkin are picrosides I and II, which are iridoid glycosides.
A standardized fraction known commercially as "Picroliv," normally obtained from 3–4 year old roots and rhizomes, constitutes an important component of many Indian herbal preparations used mainly for the treatment of a variety of liver ailments. It is an iridoid glycoside mixture containing 60% picroside I and kutkoside in the ratio of 1:1.5.
In addition to its major constituents, this plant also contains several minor phytochemicals, including pikuroside, phenolic glycosides, veronicosides, 4-hydroxy-3-methoxy acetophenone, and cucurbitacin glycosides. Other compounds present are picein, androsin, drosin, and various monocyclic phenolic compounds such as apocyanin, mannitol, cinnamic acid, ferulic acid, and vanillic acid.
Triterpenes are classified as cucurbitacins. Researchers have discovered several new cucurbitacin derivatives from this plant, which have cytotoxic and antitumor effects.
The principal active component of P. kurroa extract for liver protection is kutkin. The hepatoprotective activity of kutkin is mainly due to the suppression of xanthine oxidase, metal-ion chelation, inhibition of oxygen anion generation, free radical scavenging, and anti-lipid peroxidation.
Animal and laboratory studies strongly suggest that Picrorhiza may protect liver cells via mechanisms including stimulation of growth and regeneration of damaged liver tissues, in a manner similar to the silymarin flavonoid from milk thistle.
The mechanism of action of kutkins appears to be the same as that of silymarin (the active constituent and hepatoprotective constituent of Silybum marianum). Studies have shown that kutkins are more potent than silymarin as far as hepatoprotective activity is concerned.
Kutkin also appears to have choleretic effects that surpass those of silymarin in potency.
The active constituent kutkin, picroside-1, and kutkoside have demonstrated high anti-inflammatory activity in a variety of test models, showing significant anti-inflammatory activity in adjuvant-induced arthritis and formaldehyde arthritis in rats and mice. Among these constituents, apocynin was found to have NADPH oxidase inhibition ability, thereby inhibiting the production of reactive oxygen species (ROS) by polymorphonuclear leukocytes.
In the respiratory system, kutki has demonstrated the ability to reduce the severity and longevity of asthmatic attacks, effects attributed to compounds such as androsin and apocynin.
Kutki is a strong immunomodulatory agent that modulates antibody and macrophage activity and also the non-specific immune response. It is also a strong antibacterial agent.
Evidence strength: Moderate (animal/preclinical strong; human clinical limited but positive)
Extracts have been found to protect hepatocytes from a variety of insults, including those due to amanitin, phalloidin, carbon tetrachloride, galactosamine, ethanol, aflatoxin B1, oxytetracyclines, and monocrotaline.
Picroliv has shown efficacy comparable to silymarin in rodent models of galactosamine, paracetamol, thioacetamide, and CCl4-induced hepatic damage.
A key clinical study (PubMed PMID: 9715310) was a randomized, double-blind, placebo-controlled trial in humans: In this trial involving patients with acute viral hepatitis (HBsAg negative), P. kurroa root powder at 375 mg three times a day was given for 2 weeks (n=15) or a matching placebo (n=18). The difference in values of bilirubin, SGOT, and SGPT was significant between placebo and P. kurroa groups. The time in days required for total serum bilirubin to drop to an average value of 2.5 mg% was 75.9 days in the placebo group as against 27.44 days in the P. kurroa group.
Some early-phase clinical studies in humans have suggested that extracts of Picrorhiza kurroa containing kutkin can improve biochemical markers in certain liver disorders, such as viral hepatitis and fatty liver disease. However, these studies are generally limited by small sample sizes and methodological variations. While the existing evidence is promising, large-scale, well-controlled human clinical trials specifically focusing on kutkin are still lacking.
Kutki is an important medicinal plant traditionally used in Ayurveda for millennia. There has been a significant revival of keen interest in its pharmacology and phytochemistry in recent decades. The evidence of its hepatoprotective activity in experimental and clinical studies has accelerated the correlation of specific phytochemical constituents of P. kurroa with precise pharmacological activities, with iridoid glycosides — particularly picrosides — emerging as the active molecules.
In summary, the compounds found in the roots and rhizomes of P. kurroa have been used for centuries in Ayurvedic medicine. The research shows apparent beneficial effects, with convincing studies in cell cultures and animal models as well as a few positive clinical studies.
Evidence strength: Preliminary (limited early clinical trials, primarily animal/in vitro)
Several early clinical investigations were conducted in India. A preliminary clinical trial of Picrorhiza kurroa in bronchial asthma was reported in the Indian Journal of Pharmacology in 1975 (Rajaram D.). Doshi et al. published results of a study specifically examining Picrorhiza kurroa in bronchial asthma in the Journal of Postgraduate Medicine in 1983. These are early-phase, small trials; no large or recent randomized controlled trials were identified for this indication.
The antiasthmatic mechanism has been attributed to specific compounds: Dorsch et al. reported that antiasthmatic effects of Picrorhiza kurroa are attributable to androsin, which prevents allergen- and PAF-induced bronchial obstruction in guinea pigs.
Evidence strength: Preclinical (animal and in vitro); no large human RCTs identified
Many authors have reported the anti-inflammatory effects of this plant. Kutkin, the bioactive constituent of the alcoholic root extract, was found to be responsible for anti-inflammatory activity.
In comprehensive reviews, the phytoconstituents of P. kurroa have been examined for substantial pharmacological activities, including antimicrobial, anti-inflammatory, anticancer, immunomodulatory, antidiabetic, antioxidant, hepatoprotective, anti-ulcer, cardioprotective, hypolipidemic, and other activities.
Evidence strength: Preliminary (animal models; early human data limited)
Puri et al. reported immunostimulant activity of Picroliv, the iridoid glycoside fraction of Picrorhiza kurroa, and its protective action against Leishmania donovani infection in hamsters.
A study (PubMed PMID: 9820126) investigated Picroliv against Leishmania donovani: Picroliv, a standardized mixture of iridoid glycosides from the alcoholic extract of the root and rhizome of Picrorhiza kurroa, has shown strong hepatoprotective activity against several models of hepatotoxicity. A study was undertaken to study the effects of Picroliv (12.5 mg/kg × 7 days orally) alone and in combination with sodium stibogluconate on parasitemia, lipid peroxidation, and hepatic marker enzymes of golden hamsters during Leishmania donovani infection.
Evidence strength: Preliminary (one early clinical observation study)
Bedi KL et al. published a study titled "Picrorhiza kurroa, an Ayurvedic herb, may potentiate photochemotherapy in vitiligo" in the Journal of Ethnopharmacology in 1989. This work suggested that the herb might enhance the response to PUVA therapy (psoralen plus ultraviolet-A light) in vitiligo. This is a single early study, and the evidence for this application is considered preliminary.
Evidence strength: In vitro only; no human clinical trials identified
An extract of P. kurroa was evaluated for potential antimicrobial activity. The ethanolic extract showed effective antimicrobial activity (zone of inhibition: 29.8 mm, MIC: 2.45 mg/mL, MBC: 2.4 mg/mL) against Yersinia enterocolitica. Potential bioactive compounds were identified using LC–MS, including cerberidol, annonidine A, benzyl formate, picroside-1, and furcatoside A.
Evidence strength: Animal/preclinical; traditional use well documented
Healing of indomethacin-induced gastric ulcer in rats through in vivo free radical scavenging activity of ethanolic extract of P. kurroa root has been observed at a dose of 20 mg/kg body weight. Normal levels of peroxidized fat (thiobarbituric acid reactive species, TBARS) and increased activity of antioxidant enzymes (SOD, catalase, and total sulfhydral groups) were observed in ulcerated rats treated with the extract.
Evidence strength: Preclinical (animal and cell culture only)
P. kurroa extract and its isolated iridoid glycosides (picrosides I, kutkoside, and kutkin) have shown anti-invasion activity in MCF-7 cells (human breast cancer) by downregulation of the expression of matrix metalloproteinases (MMPs), specifically MMP-2, -9 and MMP-1, 13. These proteinases are involved in invasion and migration of solid tumors.
Rajeshkumar and Kuttan reported the protective effect of Picroliv, the active constituent of Picrorhiza kurroa, against chemical carcinogenesis in mice, published in Teratogenesis, Carcinogenesis, and Mutagenesis in 2001. No human clinical trials for cancer applications have been identified in the literature.
Different pharmacological activities of P. kurroa recorded include nephroprotective activity, anti-ulcer, anti-inflammatory, antidiabetic, antimalarial, hepatoprotective, cardioprotective, antimutagenic, antibacterial, antioxidant, antimicrobial, and anticancer effects.
Dosages noted in the scientific literature and clinical studies are as follows:
A pharmacokinetic study in rats compared oral administration of three different preparations: kutkin (a mixture of picrosides I and II), P. kurroa extract, and Picrolax® capsule (a marketed formulation). The results showed a significant difference (p≤0.05) in oral bioavailability of picrosides I and II from different preparations. Both compounds were found to be more bioavailable from P. kurroa extract, followed by Picrolax® capsule and then pure kutkin.
Kutkin also appears to be quite non-toxic; in rats, the median lethal dose for the extract administered orally is greater than 2,600 mg/kg body weight. There have been no reports of hepatotoxicity ascribed to kutkin.
No major adverse effects have been reported for this plant.
It is difficult to make definitive statements about its clinical use, although its long history of use in Indian traditional medicine and recently performed clinical trials indicate that it is very non-toxic and is associated with only occasional mild side effects.
In order to meet market demands, P. kurroa is often adulterated with other species of Picrorhiza and Lagotis cashmeriana Rupr. (Plantaginaceae). Lagotis cashmeriana is found growing with P. kurroa at similar elevations and habitat of alpine Himalayas, between 3,200 and 4,500 m, and it is traded under the same name of Kutki.
In 1997, kutki was listed in Appendix II of the Convention on International Trade in Endangered Species (CITES), following a request by the Indian government. Overharvesting of the wild species for use as medicine was cited as the main reason for the listing.
In India, the species receives protection at the state level, where it is classified as endangered in Jammu and Kashmir and Himachal Pradesh, and critically endangered in Uttarakhand, with bans on wild collection enforced in these regions to curb illegal harvesting.
Around 300–400 plants are uprooted to obtain 1 kg of roots. Kutki is listed in CITES Appendix II and the Indian Red List of endangered species, which restricts the trade of non-cultivated and non-traceable kutki obtained from the wild.
Picrorhiza kurrooa is also listed in Appendix II of CITES. In Canada, the species is protected under the Wild Animal and Plant Protection and Regulation of International and Interprovincial Trade Act (WAPPRIITA), requiring CITES import/export permits with each shipment.
Ayurvedic formulations containing P. kurroa must be scientifically validated by modern analytical tools. The isolated compounds need to be pharmacologically evaluated to validate the traditional medicinal significance of P. kurroa, as most of the activities have been performed on extracts/fractions or primarily on a few picrosides.
Studies in humans are generally limited by small sample sizes and methodological variations. Large-scale, well-controlled human clinical trials specifically focusing on kutkin are still lacking.
Health conditions that Kutkins may help support.
Body systems that Kutkins may help support.
Go back